Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
investing
9
×
life sciences
national blog main
boston blog main
clinical trials
san francisco blog main
boston top stories
deals
national top stories
san francisco top stories
cancer
fda
new york blog main
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer immunotherapy
eli lilly
pfizer
president trump
alexion pharmaceuticals
bristol-myers squibb
What
drug
9
×
roundup
bio
medicines
cancer
fda
alzheimer’s
annual
approved
attention
biotech
companies
disease
ipo
plan
prices
research
therapeutics
year
advantages
affects
ahead
ambien
american
americans
approval
asco
assessed
attendees
bacteria
bar
biopharma
blueprint
brings
business
camp’s
candidate
cash
chicago
city
Language
unset
Current search:
investing
×
drug
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More